What You Should Know:
- Haystack Oncology ("Haystack"), an oncology company that applies the next generation of circulating tumor DNA (ctDNA) detection technology raises $56M in Series A financing led by Catalio Capital Management ("Catalio"), which co-founded Haystack through its private equity and structured equity investment vehicles. Additional investors include Bruker, Exact Ventures, the venture arm of Exact Sciences and Alexandria Venture
Read More
Oncology Technology Solutions, Services Impacting Patients and Providers
ConcertAI Names Ronan Brown as its First COO
What You Should Know:
- ConcertAI, which provides AI SaaS and real-world data tech solutions for oncology research and trials, today announced the appointment of Ronan Brown as its first COO.
- In his new role as COO, Brown will oversee and enhance day-to-day operations across the company, globally, to assure the quality, performance, and seamless functionality of the company’s solutions as the ConcertAI continues it high growth.
- Brown, who was most recently senior vice
Read More
HLTH22 Day 1 News Summary: Google, Maven, Highmark, LG, Others
Venture Capital, Private Equity Funding
Maven Clinic Secures $90M to Advance End-to-End Family Care Platform
Maven Clinic, the largest virtual clinic in women’s and family health raises $90 million Series E funding bringing its total funding to $300M. Maven plans to use the latest round of funding to advance its end-to-end family care platform to enable deeper personalization to meet the diverse needs of women and families everywhere.
Curavit Raises $5M for Digital Therapeutics
Read More
HLTH22: COTA and Google Partner to Use NLP to Harness Unstructured Oncology Data
What You Should Know:
COTA, Inc., an oncology real-world data and analytics company announced a partnership with Google Cloud to bring clarity to unstructured oncology data through the latest advancements in machine learning and natural language processing.
- Many leading real-world data companies - including COTA - leverage clinicians to manually curate oncology real-world data. While this is a reliable and trusted near-term solution to overcoming the challenges associated with
Read More
ConcertAI CEO Talks COVID-19 & The De-Risking of Technology to Keep Trials Moving
Nothing like it had ever happened before – a global slowdown in new study starts and a massive decrease in trial accruals for open studies. The turn of events was a shock for sponsors and providers. Sudden disruptions on that scale rarely hit multiple players in an ecosystem at the same time. But that’s exactly what happened at the intersection of clinical care and clinical development during the pandemic. Researchers and clinicians were forced to change how they operated trials, and
Read More
JPMorgan Establishes Life Sciences Private Equity Division
What You Should Know:
- J.P. Morgan Asset Management announced the establishment of a new life sciences private equity team, Life Sciences Private Capital.
- The new team will focus on investing in both early and growth-stage healthcare companies across multiple strategies aligned to specific market opportunities, with a focus on novel therapeutics and technologies in several target areas including Genetic Medicine, Oncology, Neurodegenerative Disease, Rare Diseases, Autoimmunity,
Read More
Tempus Launches Real-World Data-Driven Program to Accelerate Precision Oncology Research
What You Should Know:
- Precision Medicine company Tempus announced the launch of Tempus+, a program connecting medical centers across the U.S. like Stanford Cancer Center, Baylor College of Medicine, Rush University Medical Center, and UCLA Jonsson Comprehensive Cancer Center, to advance cancer research and provide access to Tempus’ library of more than five million de-identified research records.
- Tempus’ data library and data analytics platform, Lens, can now be used by researchers to
Read More
COTA Secures New Financing to Accelerate Cancer Research and Treatment Innovation
What You Should Know:
- COTA, Inc., an oncology real-world data and analytics company, announced its latest financing by an investment fund managed by Deerfield Management and additional capital from existing investors.
- The company will use this new funding to further expand its real-world data platform and services in order to drive more efficient and inclusive drug development in oncology.
- Perella Weinberg Partners LP served as exclusive financial advisor and Goodwin Procter
Read More
When Advancing a Medical Device, Be A Partner First & Seller Second to Hospital Systems
US hospital systems validate the safety, clinical utility, and robustness of newly FDA-approved devices, 510(k) cleared, before adopting them into clinical practice. This work occurs alongside evaluating how to integrate the medical device into the hospital system’s diagnostic paradigms, including in relation to quality improvement programs. Companies can have a role but there are 415 US hospital systems (comprising ~5,000 hospitals), and each has a bespoke process and ever-changing set of
Read More
SURGE Therapeutics Raises $26M to Accelerate Intraoperative Immunotherapy
What You Should Know:
- SURGE Therapeutics (SURGE) recently announced the completion of a $26 million Series A financing led by Camford Capital, with participation from Khosla Ventures, Intuitive Ventures, Pitango HealthTech, 8VC, Alumni Ventures, and the Cancer Research Institute.
- The funds will be used to accelerate the development of the SURGE™ intraoperative immunotherapy approach, expand the team, and initiate clinical trials for its injectable biodegradable hydrogel.
Using
Read More
